FGF2 and neoplasm: Sulfatinib indeed inhibited bFGF- induced CAF phenotype and CAF activation in the transcriptional and protein levels, which suggested that targeting CAF is the indirect mechanism in which sulfatinib exerts its effective anti-tumor effects.